BAG3 as a target for therapy of heart failure
Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
1. A method of treating a human patient suffering from heart failure with reduced ejection fraction, wherein the human patient expresses a decreased level of BCL2-associated athanogene 3 (BAG3) polynucleotide or polypeptide, comprising:
administering to the human patient a therapeutically effective amount of an isolated BAG3 gene, BAG3 polynucleotide, BAG3 protein, BAG3 polypeptide or an expression vector comprising a BAG3 polynucleotide or cDNA sequence thereof to increase expression or amount of BAG3 polypeptides or proteins in a target cell or tissue in the human patient.
2. The method of claim 1 , wherein the human patient has a mutation in their BAG3 polynucleotide or polypeptide.
3. The method of claim 1 , wherein the expression vector comprises a viral vector, eukaryotic or prokaryotic plasmid, or yeast vector.
4. The method of claim 3 , wherein the viral vector comprises an adeno-associated virus vector (AAV), adenovirus vector, coxsackie virus vector, a cytomegalovirus vector, a lentivirus or retroviral vector.
5. The method of claim 4 , wherein the adeno-associated virus comprises: serotype 1 (AAV1), serotype 2 (AAV2), serotype 3 (AAV3), serotype 4 (AAV4), serotype 5 (AAV5), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), or serotype 9 (AAV9) capsid protein.
6. The method of claim 1 , wherein heart failure with reduced ejection fraction is identified by:
obtaining a biological sample from the human patient; and
detecting a mutation in BAG3 molecules and/or measuring the level of BAG3 polynucleotide or polypeptide in the biological sample wherein a decreased level of BAG3 molecules as compared to a normal control is indicative of heart failure with reduced ejection fraction in the human patient.
7. A method of treating a human patient suffering from heart failure with reduced ejection fraction, comprising:
obtaining a biological sample from a human patient;
measuring the level of BCL2-associated athanogene 3 (BAG3) polynucleotides, polypeptides in the biological sample and/or detecting a mutation in a BAG3 polynucleotide or polypeptide; and,
administering a BAG3 polynucleotide, expression vector comprising a BAG3 polynucleotide or cDNA sequence thereof, or polypeptide to the human patient if the human patient expresses a decreased level of BAG3 polynucleotide or polypeptide compared to control.
8. The method of claim 1 , wherein the human patient suffers from familial dilated cardiomyopathy.
9. The method of claim 1 , wherein the human patient suffers from non-familial dilated cardiomyopathy.
10. The method of claim 7 , wherein the human patient suffers from familial dilated cardiomyopathy.
11. The method of claim 7 , wherein the human patient suffers from non-familial dilated cardiomyopathy.
12. The method of claim 1 , wherein the BAG3 gene, BAG3 polynucleotide, BAG3, protein, BAG3 polypeptide or an expression vector comprising a BAG3 polynucleotide or cDNA sequence thereof is comprised in a pharmaceutical composition.
13. The method of claim 7 , wherein the BAG3 polynucleotide, expression vector comprising a BAG3 polynucleotide or cDNA sequence thereof, or polypeptide administered to the human patient is comprised in a pharmaceutical composition.
14. The method of claim 1 , wherein the expression vector comprising a BAG3 polynucleotide or cDNA sequence thereof further comprises a cardiac specific promoter.
15. The method of claim 14 , wherein the expression vector comprising the BAG3 polynucleotide or cDNA sequence that further comprises a cardiac specific promoter is flanked by one or more inverted terminal repeats (ITRs).
16. The method of claim 15 , wherein the one or more ITRs comprise AAV2 ITRs.
17. The method of claim 7 , wherein the expression vector comprising a BAG3 polynucleotide or cDNA sequence thereof further comprises a cardiac specific promoter.
18. The method of claim 17 , wherein the expression vector comprising the BAG3 polynucleotide or cDNA sequence that further comprises a cardiac specific promoter is flanked by one or more inverted terminal repeats (ITRs).
19. The method of claim 18 , wherein the one or more ITRs comprise AAV2 ITRs.
20. The method of claim 1 , wherein the human patient suffers from ischemic heart disease.
21. The method of claim 7 , wherein the human patient suffers from ischemic heart disease.
22. The method of claim 1 , wherein the human patient suffers from non-ischemic cardiomyopathy.
23. The method of claim 7 , wherein the human patient suffers from non-ischemic cardiomyopathy.